1 citations,
March 2023 in “Clinical, Cosmetic and Investigational Dermatology” Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.
1 citations,
December 2013 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” New treatments and strategies are needed for Alopecia Areata, focusing on immune response and better trial designs.
1 citations,
May 2022 in “Frontiers in Pharmacology” Astilbin can potentially calm overactive immune responses, like in Type 1 Diabetes, by suppressing certain cell activities and reducing inflammation.
May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
April 2024 in “Journal of translational medicine” MJ04, a new compound, effectively promotes hair growth and is a potential topical treatment for hair loss.
April 2024 in “International journal of molecular sciences” Alopecia areata and vitiligo share immune system dysfunction but differ in specific immune responses and affected areas.
March 2024 in “Nutrients” Alopecia Areata is linked to specific gut bacteria and metabolites, indicating a complex gut microbiome.
March 2024 in “International Journal of Cosmetic Science” Dandruff is linked to increased T cells and weakened immune protection in hair follicles.
January 2024 in “International Journal of Molecular Sciences” Blocking the protein CXCL12 with a specific antibody can increase hair growth in common hair loss conditions.
October 2023 in “International journal of rheumatic diseases” New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
July 2023 in “IntechOpen eBooks” New treatments for alopecia areata show promise, but more research is needed to confirm their effectiveness.
May 2023 in “Journal of Clinical Medicine” New understanding and treatments for hair loss are improving, but more research is needed.
January 2023 in “Karger Kompass. Dermatologie” Scientists are still unsure what triggers the immune system to attack hair follicles in Alopecia areata.
December 2022 in “Dermatology and Therapy” Alopecia areata needs more recognition and better treatment access in Latin America to improve patient care and outcomes.
March 2022 in “Wound practice & research” New treatments for alopecia areata show promise, but standardized guidelines are needed.
July 2021 in “IntechOpen eBooks” Ginseng, especially its component ginsenosides, can promote hair growth, reduce hair loss, and potentially treat conditions like alopecia by affecting cell pathways and cytokines.
July 2019 in “Dermatology practical & conceptual” The study found that alopecia areata is strongly linked to autoimmune diseases and may indicate a genetic predisposition to such conditions.
March 2017 in “Current dermatology reports” Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.
January 2017 in “Journal of Investigative Dermatology Symposium Proceedings” The 2015 Hair Research Congress concluded that stem cells, maraviroc, and simvastatin could potentially treat Alopecia Areata, topical minoxidil, finasteride, and steroids could treat Frontal Fibrosing Alopecia, and PTGDR2 antagonists could also treat alopecia. They also found that low-level light therapy could help with hair loss, a robotic device could assist in hair extraction, and nutrition could aid hair growth. They suggested that Alopecia Areata is an inflammatory disorder, not a single disease, indicating a need for personalized treatments.
August 2024 in “Current Protocols” The C3H/HeJ mouse model is useful for studying and testing treatments for alopecia areata.
July 2024 in “International Journal of Molecular Sciences” Hemp seed biomaterials may reduce hair loss and improve hair growth.
June 2024 in “Frontiers in immunology” Sequential therapy with dupilumab and baricitinib improved hair regrowth and atopic dermatitis in a child without adverse reactions.
February 2024 in “The Open dermatology journal” Alopecia Areata affects people of all ages worldwide, is likely caused by genetic and environmental factors, and can lead to stress and depression, highlighting the need for treatments that address both physical and mental health.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
July 2023 in “Skin Research and Technology” Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.
February 2022 in “International journal of KIU” Certain genes and nutrients like vitamin D, zinc, and omega fatty acids affect COVID-19 severity and infection risk.
16 citations,
March 2018 in “Seminars in Oncology” The document concludes that pregnancy and cancer share immune evasion tactics, but more research is needed before using checkpoint blockade immunotherapy in pregnant cancer patients to avoid harm to the placenta.
14 citations,
February 2023 in “Frontiers in immunology” Immune checkpoint inhibitors can cause skin issues but are linked to better cancer outcomes.
2 citations,
May 2018 in “Expert opinion on orphan drugs” Newborn screening and gene therapy are expected to improve outcomes for Omenn syndrome patients.
June 2020 in “Journal of Dermatological Treatment” Use telemedicine and strict hygiene for safe hair and scalp treatments during COVID-19.